Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-28

Study Completion Date

2011-01-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine the effects of co-administration of SPD489 and the antidepressant EFFEXOR XR on the pharmacokinetics of lisdexamfetamine, d-amphetamine, and EFFEXOR XR. In addition, serial blood pressure and pulse measures will be obtained and examined to ensure that there are no unexpected changes in vital signs following co administration of SPD489 and EFFEXOR XR that would impact the further study of this drug combination. The hypothesis is that a drug drug interaction could possibly exist.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424

Major Depressive Disorder

COMPLETED PHASE2

Aripiprazole and Effexor XR Drug Interaction Study

NCT00362271

Healthy

COMPLETED PHASE1

Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression

NCT06967857

Attention-Deficit/Hyperactivity Disorder (ADHD) Depression - Major Depressive Disorder

RECRUITING PHASE2

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

NCT02637193

Healthy Subjects

COMPLETED PHASE1

Project to Improve Symptoms and Mood in People With Spinal Cord Injury

NCT00592384

Major Depressive Disorder Dysthymia Spinal Cord Injuries

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LDX (SPD489) + Venlafaxine XR (Effexor XR)

Group Type EXPERIMENTAL

LDX + Venlafaxine XR

Intervention Type DRUG

* Day 1-5 LDX 30mg
* Day 6-10 LDX 50mg
* Day 11-15 LDX 70mg
* Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily
* Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily
* Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily
* Day 31-34 Venlafaxine XR 150mg daily
* Day 35-38 Venlafaxine XR 75mg daily.

Venlafaxine XR + LDX

Group Type EXPERIMENTAL

Venlafaxine XR + LDX

Intervention Type DRUG

* Day 1-5 Venlafaxine XR 75mg
* Day 6-10 Venlafaxine XR 150mg
* Day 11-15 Venlafaxine XR 225mg
* Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily
* Day 21-25 Venlafaxine XR and LDX 50mg daily
* Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily
* Day 31-34 Venlafaxine XR 150mg
* Day 35-38 Venlafaxine XR 75mg.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LDX + Venlafaxine XR

* Day 1-5 LDX 30mg
* Day 6-10 LDX 50mg
* Day 11-15 LDX 70mg
* Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily
* Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily
* Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily
* Day 31-34 Venlafaxine XR 150mg daily
* Day 35-38 Venlafaxine XR 75mg daily.

Intervention Type DRUG

Venlafaxine XR + LDX

* Day 1-5 Venlafaxine XR 75mg
* Day 6-10 Venlafaxine XR 150mg
* Day 11-15 Venlafaxine XR 225mg
* Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily
* Day 21-25 Venlafaxine XR and LDX 50mg daily
* Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily
* Day 31-34 Venlafaxine XR 150mg
* Day 35-38 Venlafaxine XR 75mg.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lisdexamfetamine dimesylate, LDX, Vyvanse, SPD489; Venlafaxine hydrochloride extended-release, Effexor XR, Venlafaxine hydrochloride extended-release, Effexor XR; Lisdexamfetamine dimesylate, LDX, Vyvanse, SPD489

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-45 years
2. Subject is willing to comply with any applicable contraceptive requirements of the protocol and is:

* Male, or
* Non-pregnant, non-lactating female
* Females must be at least 90 days post partum or nulliparous.
3. Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test
4. Satisfactory medical assessment
5. Ability to provide information on family history of hypertension.
6. Body Mass Index (BMI) between 18.5 and 30.0kg/m² inclusive.
7. Ability to swallow all investigational products.

Exclusion Criteria

1. Current or recurrent disease (e.g., cardiovascular, renal, liver, gastrointestinal, malignancy or other conditions)
2. Current or relevant previous history of physical or psychiatric illness.
3. Significant illness.
4. History of significant anxiety, tension, or agitation as assessed by the Investigator.
5. History of or current diagnosis of glaucoma.
6. History of a seizure disorder (other than infantile febrile seizures), any tic disorder or a current diagnosis and/or known family history of Tourette's Disorder.
7. History of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, transient ischemic attack or stroke, or other serious cardiac problems.
8. History of controlled or uncontrolled hypertension or a resting sitting systolic BP \>139mmHg or diastolic BP \>89mmHg.
9. Known family history of sudden cardiac death or ventricular arrhythmia.
10. Suicidal ideation or any lifetime history of suicidal behavior.
11. Consumption of alcohol, Seville oranges, grapefruit, or any grapefruit containing products within 7 days of first dose of investigational product.
12. Current use of any medication (including prescription, over the counter \[OTC\], herbal or homeopathic preparations or supplements) with the exception of the occasional dose of acetaminophen, or hormonal contraceptives.
13. History of alcohol or other substance abuse within the last year.
14. A positive screen for alcohol or drugs of abuse.
15. Male subjects who consume more than 21 units of alcohol per week or 3 units per day. Female subjects who consume more than 14 units of alcohol per week or 2 units per day. \[1 alcohol unit =1 beer = 1 wine (5oz) = 1 liquor (1.5oz) = 0.75oz alcohol\]
16. A positive human immunodeficiency virus (HIV) antibody screen, Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody screen.
17. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g. gum, patch). Ex-users must report that they have stopped using tobacco for at least 30 days prior to receiving the first dose of investigational product.
18. Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6oz. cup of coffee, two 12oz. cans of cola, one 12oz. cup of tea, three 1oz. chocolate bars, or one 8oz. serving of an energy drink. Decaffeinated coffee, tea, or cola are not considered to contain caffeine).
19. Donation of blood or blood products (e.g., plasma or platelets) within 60 days prior to receiving the first dose of investigational product.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes